609 related articles for article (PubMed ID: 25220794)
21. Potential role of nutraceutical compounds in inflammatory bowel disease.
Larussa T; Imeneo M; Luzza F
World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
[TBL] [Abstract][Full Text] [Related]
22. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease.
Fiorino G; Correale C; Fries W; Repici A; Malesci A; Danese S
Expert Rev Clin Immunol; 2010 Jul; 6(4):567-72. PubMed ID: 20594130
[TBL] [Abstract][Full Text] [Related]
23. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
McLean LP; Cross RK
Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
[TBL] [Abstract][Full Text] [Related]
24. Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.
Krupka N; Baumgart DC
Drug Des Devel Ther; 2015; 9():147-54. PubMed ID: 25552903
[TBL] [Abstract][Full Text] [Related]
25. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
26. Emerging immunological targets in inflammatory bowel disease.
Monteleone G; Pallone F; MacDonald TT
Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
[TBL] [Abstract][Full Text] [Related]
27. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.
Sugiura T; Kageyama S; Andou A; Miyazawa T; Ejima C; Nakayama A; Dohi T; Eda H
J Crohns Colitis; 2013 Dec; 7(11):e533-42. PubMed ID: 23623333
[TBL] [Abstract][Full Text] [Related]
28. Serum sickness, encephalitis and other complications of anti-cytokine therapy.
Vermeire S; Van Assche G; Rutgeerts P
Best Pract Res Clin Gastroenterol; 2009; 23(1):101-12. PubMed ID: 19258190
[TBL] [Abstract][Full Text] [Related]
29. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.
Tilg H; Kaser A
Curr Opin Investig Drugs; 2010 Nov; 11(11):1295-304. PubMed ID: 21157649
[TBL] [Abstract][Full Text] [Related]
30. Vedolizumab for the treatment of ulcerative colitis.
Rietdijk ST; D'Haens GR
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
[TBL] [Abstract][Full Text] [Related]
31. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing.
Zundler S; Neurath MF
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S19-28. PubMed ID: 26458165
[TBL] [Abstract][Full Text] [Related]
32. PECAM-1 (CD 31) mediates transendothelial leukocyte migration in experimental colitis.
Rijcken E; Mennigen RB; Schaefer SD; Laukoetter MG; Anthoni C; Spiegel HU; Bruewer M; Senninger N; Krieglstein CF
Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G446-52. PubMed ID: 17510197
[TBL] [Abstract][Full Text] [Related]
33. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM
Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644
[TBL] [Abstract][Full Text] [Related]
34. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target.
Allocca M; Fiorino G; Vermeire S; Reinisch W; Cataldi F; Danese S
Expert Rev Clin Immunol; 2014 Jul; 10(7):885-95. PubMed ID: 24813675
[TBL] [Abstract][Full Text] [Related]
35. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases.
Luzentales-Simpson M; Pang YCF; Zhang A; Sousa JA; Sly LM
Front Cell Dev Biol; 2021; 9():612830. PubMed ID: 33614645
[TBL] [Abstract][Full Text] [Related]
36. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
37. Controlling leukocyte trafficking in IBD.
Veny M; Fernández-Clotet A; Panés J
Pharmacol Res; 2020 Sep; 159():105050. PubMed ID: 32598943
[TBL] [Abstract][Full Text] [Related]
38. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
Lord JD; Long SA; Shows DM; Thorpe J; Schwedhelm K; Chen J; Kita M; Buckner JH
Clin Immunol; 2018 Aug; 193():24-32. PubMed ID: 29842945
[TBL] [Abstract][Full Text] [Related]
39. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
Zundler S; Becker E; Schulze LL; Neurath MF
Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
[TBL] [Abstract][Full Text] [Related]
40. Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
Khanna R; Mosli MH; Feagan BG
Dig Dis; 2016; 34(1-2):153-9. PubMed ID: 26982012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
